Brief: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
24/06/2025 13:12
June 24 (Reuters) - Sangamo Therapeutics Inc SGMO.O: SANGAMO THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE SANGAMO THERAPEUTICS INC - ISARALGAGENE CIVAPARVOVEC SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE SANGAMO THERAPEUTICS INC - TO SUBMIT BLA IN 2026 SANGAMO THERAPEUTICS INC - STAAR STUDY SHOWS POSITIVE MEAN ANNUALIZED EGFR SLOPE AT 52 WEEKS Source text: ID:nBwbmFVVVa Further company coverage: SGMO.O ((Reuters.Briefs@thomsonreuters.com;))